Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors

Muth KN, Rech J, Losch FO, Hörning A (2023)

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Journal of Clinical Medicine MDPI

Book Volume: 12

Article Number: 5039

Journal Issue: 15

DOI: 10.3390/jcm12155039

Abstract

Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, peripheral and/or axial spondyloarthritis, Crohn’s disease, and ulcerative colitis, are characterized by molecular and cellular changes in the immune system. Due to the systemic nature of these diseases, organs such as the liver or cardiovascular system are often affected by the inflammatory process. Tumor necrosis factor-α inhibitor therapy reduces the activation of pro-inflammatory signaling cascades, mitigates the chronic inflammatory process by restoring cellular balance, and alleviates clinical consequences, such as pain and tissue damage.

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology André Hörning Department of Paediatrics and Adolescent Medicine

Involved external institutions

Hexal AG DE Germany (DE)

How to cite

APA:

Muth, K.N., Rech, J., Losch, F.O., & Hörning, A. (2023). Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors. Journal of Clinical Medicine, 12(15). https://doi.org/10.3390/jcm12155039

MLA:

Muth, Katharina N., et al. "Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors." Journal of Clinical Medicine 12.15 (2023).

BibTeX: Download